Associate Professor Murdoch University Kardinya, Western Australia, Australia
Disclosure(s):
Claire R. Sharp, BVMS(Hons), MS, DACVECC: No financial relationships to disclose
This session will review the 8 published manuscripts that make up the ACVECC consensus guidelines (CURATIVE) for the use of antithrombotic and thrombolytics in small animals, including the 2022 updates to these consensus guidelines. Specifically we will review how the guidelines help us answer clinical questions such as whether or not thromboprophylaxis or a thrombolytic agent is indicated in an individual dog or cat patient and if so, what drug, dose, monitoring and duration of therapy is appropriate. We’ll cover thrombosis risk associated with diseases such as IMHA, PLN, PLE, and cardiac disease in cats, as well as a variety of thromboprophylactic drugs.
Learning Objectives:
Identify at-risk populations for thrombosis, and classify patients into high, and moderate/low risk categories for thrombosis based on the 2019 and 2022 CURATIVE guidelines.
Apply rational thromboprophylaxis strategies: Select appropriate antithrombotic agents and monitoring approaches based on patient risk, drug class, and available evidence, while balancing efficacy and safety.
Describe the current evidence and recommendations for the rational use of thrombolytics in dogs and cats, including indications, limitations, and safety considerations, and how these differ from antithrombotic therapy.
